Robbie Stephens Downgrades Guidant

Analyst Wade King says an FDA panel's rejection of the company's heart-failure device means its rival could corner the market

Robertson Stephens downgraded Guidant Corp. (GDT ) to market perform from buy and cut its estimates for the medical-device maker.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.